IPP Bureau
India's digital startup ecosystem a catalyst for global healthcare transformation: Piyush Goyal
By IPP Bureau - September 02, 2023
Robots make it to the healthcare conference panel, reflecting the future potential of technology
USFDA delegation visits Amneal Pharmaceutical facility in Matoda
By IPP Bureau - September 02, 2023
Amneal’s site in Matoda is one of the company’s 12 pharmaceutical manufacturing facilities
Jupiter Life Line Hospitals’ IPO to open on Sept. 6
By IPP Bureau - September 02, 2023
Sets price band at ?695 to ?735 per Equity Share
Global health challenges can be resolved using digital technology: Dr Alain Labrique
By IPP Bureau - September 02, 2023
Biocon acquires oral solid dosage manufacturing facility of Eywa Pharma for US$7.7 million
By IPP Bureau - September 02, 2023
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Shilpa Pharma Lifesciences’ Unit II, Raichur, Karnataka clears PMDA Japan, GMP inspection
By IPP Bureau - September 02, 2023
The inspection has concluded successfully on 1st September 2023 without any critical/major observation
Sanofi, Meningitis Research Foundation and CoMO launch awareness initiative on meningitis
By IPP Bureau - September 01, 2023
Meningitis still affects more than 2.5 million people globally each year
Sanofi announces changes to its Executive Committee
By IPP Bureau - September 01, 2023
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
USFDA approves BMS’ Reblozyl as first-line treatment of anemia in adults with Myelodysplastic Syndromes
By IPP Bureau - September 01, 2023
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Elekta and IAEA partner to improve access to cancer care in underserved countries
By IPP Bureau - September 01, 2023
Dr. Laurent Leksell, Elekta’s Founder and Chairman of the Board, and IAEA’s Director General, Dr. Rafael Mariano Grossi meet in Stockholm to discuss reducing the global cancer burden
Pfizer and BioNTech receive positive CHMP opinion for Omicron XBB.1.5-adapted COVID-19 vaccine
By IPP Bureau - September 01, 2023
The updated COVID-19 vaccine is tailored to the Omicron XBB.1.5 sublineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older
Strides receives USFDA approval for Mycophenolate Mofetil for oral suspension
By IPP Bureau - August 31, 2023
The approval bolsters the company's Mycophenolate Mofetil portfolio
Lupin receives USFDA approval for Pirfenidone Capsules
By IPP Bureau - August 31, 2023
Pirfenidone Capsules had estimated annual sales of USD 95 million in the US
Unichem receives ANDA approval for Prasugrel Tablets
By IPP Bureau - August 31, 2023
Prasugrel tablets are indicated to reduce the rate of thrombotic CV events
Lupin launches propranolol capsules to improve heart health in Canada
By IPP Bureau - August 31, 2023
Propranolol LA is a generic equivalent of Inderal LA
